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ABSTRACT
A complete oncofertility counselling should be offered to all premenopausal 
patients before the administration of anticancer treatments. This important discussion 
is a crucial step for allowing them to take fully informed decisions about the proposed 
therapy and its potential long-term consequences as well as on their need and interest 
of accessing the available strategies for ovarian function and/or fertility preservation. 
In premenopausal women with HER2-positive early breast cancer, limited evidence 
exists to counsel them about the potential added gonadotoxicity of targeted agents 
beyond the damage already caused by chemotherapy. In addition, the prognostic role 
of treatment-induced amenorrhea in this setting was unknown. In our exploratory 
analysis within the ALTTO (BIG 2-06) trial, we have recently described the rates of 
treatment-induced amenorrhea after chemotherapy plus trastuzumab and/or lapatinib 
and the prognostic value of developing this side effect according to the hormone 
receptor status of their tumours. We observed similar rates of treatment-induced 
amenorrhea in the four anti-HER2 treatment arms. The lack of an increased rate of 
treatment-induced amenorrhea in the dual anti-HER2 blockade arm suggests the 
possible gonadal safety of these agents. In addition, women with HER2-positive/
hormone receptor-positive tumours showed significantly better survival outcomes if 
they developed treatment-induced amenorrhea, while no difference was observed for 
those with HER2-positive/hormone receptor-negative disease. Future research efforts 
are needed to address the gonadotoxicity of the new available targeted agents as 
well as to elucidate which is the best adjuvant endocrine therapy in premenopausal 
women with HER2-positive/hormone receptor-positive disease.
During their initial work-up, all premenopausal 
women candidates to receive chemotherapy for a newly 
diagnosed breast cancer should receive a complete 
oncofertility counselling as part of the current standard 
of care in order to be informed about the possible 
gonadotoxic risk associated with the administration of 
the proposed anticancer treatments [1]. This important 
discussion is a crucial step for allowing them to take 
fully informed decisions about the proposed therapy and 
its potential long-term consequences as well as on their 
need and interest of accessing the available strategies for 
ovarian function and/or fertility preservation. 
Menstrual function is not a perfect indicator of 
the actual treatment-induced gonadal damage that can 
potentially lead to premature ovarian insufficiency, 
infertility and early menopause; nevertheless, amenorrhea 
usually represents the first signal of chemotherapy toxic 
effects on the ovaries [2]. Experiencing treatment-induced 
amenorrhea has been shown to have a positive prognostic 
impact with improved outcomes in patients with hormone 
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receptor-positive breast cancer by causing a subsequent 
state of ovarian function suppression [3]. However, this 
can also negatively impact on women’s quality of life 
considering its associated unpleasant menopause-related 
symptoms and signs that also include possible fertility 
loss [2]. In premenopausal women with HER2-positive 
early breast cancer candidates to undergo chemotherapy 
plus 1-year of trastuzumab-based anti-HER2 treatment as 
per standard of care [1], limited evidence exists to counsel 
them about the potential added risk of gonadotoxicity with 
the administration of targeted agents beyond the damage 
already caused by systemic cytotoxic therapy. In addition, 
the prognostic role of treatment-induced amenorrhea in 
this setting was unknown.
With the final goal to provide useful information for 
improving the oncofertility counselling of premenopausal 
women with HER2-positive early breast cancer, we 
have recently performed an exploratory analysis within 
the Adjuvant Lapatinib and/or Trastuzumab Treatment 
Optimization (ALTTO; BIG 2-06) trial aiming to address 
these unmet medical issues [4]. Specifically, by including 
2,862 patients who were premenopausal at randomization, 
we described the rates of treatment-induced amenorrhea 
after approximately 9 months following the completion 
of anthracycline- and/or taxane-based chemotherapy 
in the four anti-HER2 treatment arms of the trial 
(trastuzumab alone, lapatinib alone, their sequence or 
their combination). In addition, we assessed the prognostic 
value of treatment-induced amenorrhea in patients with 
HER2-positive early breast cancer according to the 
hormone receptor status of their tumours [4]. 
The rates of treatment-induced amenorrhea were 
similar in the four anti-HER2 treatment arms, being 72.6% 
with trastuzumab alone, 74.0% with lapatinib alone, 72.1% 
with trastuzumab followed by lapatinib and 74.8% with 
dual anti-HER2 blockade of trastuzumab plus lapatinib 
(Figure 1) [4]. Notably, the ALTTO trial did not have a 
treatment arm without anti-HER2 therapies; therefore, 
the answer on the potential added gonadotoxic effect of 
trastuzumab and/or lapatinib beyond chemotherapy could 
not be addressed in our study. However, as compared to 
the trastuzumab alone arm, no increased rates of treatment-
induced amenorrhea was observed in the dual anti-HER2 
blockade arm (odds ratio, 1.19; 95% confidence intervals 
[CI], 0.94-1.51; p = 0.14) suggesting the possible gonadal 
safety of these agents, which is in line with previously 
small studies [5,6]. Therefore, the first main message from 
our analysis is that, during the oncofertility counselling of 
premenopausal women with HER2-positive early breast 
cancer, the discussion around the risk of gonadotoxicity 
with the proposed treatment as well the need for having 
access to the available strategies for ovarian function and/
or fertility preservation should be driven mostly by the 
type of chemotherapy regimen proposed and by the age 
of the patient (i.e., the two most important determinants 
of this risk). For patients who undergo temporary ovarian 
suppression with a gonadotropin-releasing hormone 
agonist during chemotherapy as a mean to reduce the 
risk of treatment-induced gonadal damage [7], our data 
(indirectly) do not support the prolongation of such 
treatment beyond systemic cytotoxic therapy and until 
the completion of 1-year of anti-HER2 therapy. Future 
Figure 1: Rates of treatment-induced amenorrhea after chemotherapy plus trastuzumab and/or lapatinib among premenopausal 
women enrolled in the ALTTO (BIG 2-06) trial.
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research efforts in the field are warranted to better elucidate 
the real impact of targeted agents including pertuzumab 
(recently approved for women with HER2-positive 
early breast cancer) on women’s ovarian reserve (e.g. by 
evaluating the dynamic of anti-mullerian hormone levels 
before and after treatment [8]). This is crucial information 
to be retrieved also considering the recent reassuring data 
on the safety and feasibility of conceiving after prior 
history of breast cancer including among premenopausal 
women with HER2-positive disease previously exposed to 
chemotherapy and anti-HER2 treatments [9].
Regarding the prognostic impact of treatment-
induced amenorrhea in premenopausal women with 
HER2-positive early breast cancer, our study showed a 
significant interaction of its effect according to hormone 
receptor status [4]. Specifically, neither difference in 
disease-free survival (adjusted hazard ratio [HR], 0.92; 
95% CI, 0.70 – 1.20) nor in overall survival (adjusted 
HR, 1.03; 95% CI, 0.68 – 1.56) were observed between 
patients with HER2-positive/hormone receptor-negative 
tumours with or without treatment-induced amenorrhea. 
On the contrary, among women with HER2-positive/
hormone receptor-positive tumours, disease-free survival 
(adjusted HR, 0.58; 95% CI, 0.45 – 0.76) and overall 
survival (adjusted HR, 0.63; 95% CI, 0.40 – 0.99) were 
significantly better for patients who developed treatment-
induced amenorrhea. Notably, the majority (67.4%) of 
premenopausal women with HER2-positive/hormone 
receptor-positive breast cancer included in the ALTTO 
trial received tamoxifen alone as adjuvant endocrine 
therapy. The recently updated SOFT trial results showed 
that the addition of ovarian function suppression to 
tamoxifen is of particular benefit for the subgroup of 
women with HER2-positive/hormone receptor-positive 
disease (pinteraction = 0.04) [10]. Our results indirectly 
support the important role of ovarian function suppression 
as part of adjuvant endocrine therapy in premenopausal 
women with HER2-positive early breast cancer. In this 
setting, the best oral endocrine partner to associate with 
ovarian function suppression remains unclear [11–13]. 
As shown in the SOFT and TEXT trial update, ovarian 
function suppression plus tamoxifen demonstrated a better 
performance than its combination with an aromatase 
inhibitor in the subgroup of premenopausal women with 
HER2-positive/hormone receptor-positive disease (i.e., an 
opposite trend as compared to the group of women with 
HER2-negative/hormone receptor-positive breast cancer) 
[10]. Similar findings have been recently shown also in 
the HOBOE trial [14]. However, no strong conclusion can 
be made considering the small number of patients with 
HER2-positive disease that were included in these trials. 
Future research efforts are awaited to answer the important 
question on which is the best oral endocrine partner to 
combine with ovarian function suppression as adjuvant 
treatment for premenopausal women with HER2-positive/
hormone receptor-positive disease.
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